Multifaceted Intervention to Improve Graft Outcome Disparities in African American Kidney Transplants (MITIGAAT Study): Protocol for a Randomized Controlled Trial.

Autor:	Overstreet M; Medical University of South Carolina, Charleston, SC, United States., Culpepper H; Medical University of South Carolina, Charleston, SC, United States., DeHoff D; Medical University of South Carolina, Charleston, SC, United States., Gebregziabher M; Medical University of South Carolina, Charleston, SC, United States., Posadas Salas MA; Medical University of South Carolina, Charleston, SC, United States., Su Z; Medical University of South Carolina, Charleston, SC, United States., Chandler J; Medical University of South Carolina, Charleston, SC, United States., Bartlett F; Medical University of South Carolina, Charleston, SC, United States., Dunton P; Medical University of South Carolina, Charleston, SC, United States., Carcella T; Medical University of South Carolina, Charleston, SC, United States., Taber D; Medical University of South Carolina, Charleston, SC, United States.
Jazyk:	angličtina
Zdroj:	JMIR research protocols [JMIR Res Protoc] 2024 Oct 10; Vol. 13, pp. e57784. Date of Electronic Publication: 2024 Oct 10.
DOI:	10.2196/57784
Abstrakt:	Background: The outcome disparities for African American recipients of kidney transplant is a public health issue that has plagued the field of transplant since its inception. Based on national data, African American recipients have nearly twice the risk of graft loss at 5 years after transplant, when compared with White recipients. Evidence demonstrates that medication nonadherence and high tacrolimus variability substantially impact graft outcomes and racial disparities, most notably late (>2 years) after the transplant. Nonadherence is a leading cause of graft loss. Prospective multicenter data demonstrate that one-third of all graft loss are directly attributed to nonadherence. We have spent 10 years of focused research to develop a comprehensive model explaining the predominant risk factors leading to disparities in African American kidney recipients. However, there are still gaps in patient-level data that hinder the deeper understanding of the disparities. Lack of data from the patient often lead to provider biases, which will be addressed with this intervention. Culturally competent, pharmacist-led interventions in medication therapy management will also address therapeutic inertia. Pharmacist interventions will mitigate medication access barriers as well (cost and insurance denials). Thus, this multidimensional intervention addresses patient, provider, and structural factors that drive racial disparities in African American kidney recipients. Objective: This prospective, randomized controlled trial aimed to determine the impact of multimodal health services intervention on health outcomes disparities in African American recipients of kidney transplant. The aims of this study are to improve adherence and control of late clinical issues, which are predominant factors for racial disparities in kidney recipients, through a technology-enabled, telehealth-delivered, 4-level intervention. Methods: The Multifaceted Intervention to Improve Graft Outcome Disparities in African American Kidney Transplants (MITIGAAT) study is a 24-month, 2-arm, single-center (Medical University of South Carolina), 1:1 randomized controlled trial involving 190 participants (95 in each arm), measuring the impact on adherence and control of late clinical issues for racial disparities in kidney recipients, through a technology-enabled, telehealth-delivered, 4-level intervention. The key clinical issues for this study include tacrolimus variability, blood pressure, and glucose control (in those with diabetes mellitus). We will also assess the impact of the intervention on health care use (hospitalizations and emergency department visits) and conduct a cost-benefit analysis. Finally, we will assess the impact of the intervention on acute rejection and graft survival rates as compared with a large contemporary national cohort. Results: This study was funded in July 2023. Enrolled began in April 2024 and is expected to be complete in 2026. All patients will complete the study by the end of 2028. Conclusions: In this protocol, we describe the study design, methods, aims, and outcome measures that will be used in the ongoing MITIGAAT clinical trials. Trial Registration: ClinicalTrials.gov NCT06023615; https://www.clinicaltrials.gov/study/NCT06023615. International Registered Report Identifier (irrid): PRR1-10.2196/57784. (©Morgan Overstreet, Hannah Culpepper, Deanna DeHoff, Mulugeta Gebregziabher, Maria Aurora Posadas Salas, Zemin Su, Jessica Chandler, Felicia Bartlett, Paige Dunton, Taylor Carcella, David Taber. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 10.10.2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu